← All trials
NCT00343798
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2006
- Primary completion
- Jul 1, 2013
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 23
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Cancer Institute (NCI)Collaborator
- Damon Runyon Cancer Research FoundationCollaborator
Drugs studied
Indications studied
- Anemia, Refractory
- Burkitt Lymphoma
- Lymphoma
- Lymphoma, Follicular
- Lymphomatoid Granulomatosis
- Multiple Myeloma
- Myelodysplastic Syndromes
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Prolymphocytic
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Acute
- Lymphoma, T-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.